Endothelin-1 (ET-1) and tumor necrosis factor-a (TNFa) participate in the cascade of luteolysis. Thus, in the present study the interactions of ET-1 and TNFa with prostaglandin F 2a (PGF 2a ) on the release of progesterone and oxytocin (OT) within the corpus luteum (CL) were investigated. A microdialysis system (MDS) was surgically implanted in ovine CL (one MDS line/CL; 5-10 lines/ewe) formed after super-ovulation. (1 mmol l 21 ), two consecutive perfusions of ET-1 decreased progesterone release more rapidly. Similarly, a pre-perfusion with PGF 2a followed by consecutive perfusions of ET-1 and then TNFa rapidly decreased progesterone release, with the inhibition most pronounced (35%) at 36 -48 h. The simultaneous infusion of ET-1 with PGF 2a induced a rapid decrease in progesterone release (36% at 36-48 h). In a further study, the possible second messenger systems involved in PGF 2a action on the release of progesterone, OT and ET-1 were investigated. A perfusion with 12-O-tetradecanoyl-phorbol-13-acetate (TPA; 10 mmol l 21 ), A23187 (10 mmol l
Introduction
It is well known that a local counter-current transfer of uterine prostaglandin F 2a (PGF 2a ) primes the luteolytic cascade of bovine corpora lutea (CL). Recent evidence in the cow suggests that endothelin-1 (ET-1), a vaso-constrictive 21-amino acid peptide, interacts with PGF 2a in the control of functional luteolysis (Girsh et al. 1996a ,b, Miyamoto et al. 1997 , Ohtani et al. 1998 , Meidan et al. 1999 . This hypothesis has been further supported by in vivo studies in the ewe. A single intra-luteal injection of BQ123, a highly specific antagonist of the endothelin type A receptor (ETA-R), at the mid luteal phase mitigated the luteolytic effect of PGF 2a (Hinckley & Milvae 2001) . This study also demonstrated that a systemic injection of ET-1 15 min after an injection of a sub-luteolytic dose of PGF 2a potentiated the decrease in plasma progesterone concentration, which resulted in the return of estrus (Hinckley & Milvae 2001) . Moreover, the administration of a luteolytic dose of PGF 2a rapidly stimulated gene expression for ET-1 in ovine CL collected at mid-cycle (Hinckley & Milvae 2001) . It is likely, therefore, that ET-1 released from microvascular endothelial cells in the CL and luteal cells (Levy et al. 2001 , Schams et al. 2003 cooperates with PGF 2a to initiate luteolysis by both directly inhibiting progesterone release (Girsh et al. 1996a , Miyamoto et al. 1997 ) via ETA-R (Girsh et al. 1996a , Hinckley & Milvae 2001 and probably by vasoconstriction of arterioles that results in an acute drop in progesterone release.
The presence of tumor necrosis factor-a (TNFa) and its receptors in the pig and bovine CL was observed by Okuda et al. (1999) , Sakumoto et al. (2000) and Miyamoto et al. (2002) and suggested that TNFa plays a significant role in the process of luteolysis (Murdoch et al. 1988 , Benyo & Pate 1992 , Shaw & Britt 1995 , Wuttke et al. 1998 . Elevated local secretion of TNFa has been found in the regressing ovine (Ji et al. 1991) and bovine (Shaw & Britt 1995) CL. Moreover, it was reported that TNFa acts synergistically with PGF 2a during the process of luteolysis in pig (Wuttke et al. 1997 (Wuttke et al. , 1998 . However, the possible synergism among PGF 2a , ET-1 and TNFa during luteolysis (Meidan et al. 1999) in the ewe is not well established. Thus, the present study was designed to examine the direct local effects and interaction of ET-1 and TNFa with PGF 2a on the release of progesterone and oxytocin (OT) within the CL, by using an in vivo microdialysis system (MDS) implanted into the CL of ewes (Miyamoto et al. 1998a,b) . This system allows cells to maintain the integrity of CL structures, and thus enables observations to be made of real-time local changes of different substances in the CL that may play a role in cell-to-cell communication.
The study was extended further to examine the possible second messenger systems involved in PGF 2a action on the release of progesterone, OT and ET-1 in the CL in vivo.
Materials and Methods

Experimental design and animals
The experiment was carried out at the Field Centre of Animal Science and Agriculture, Obihiro University and the experimental procedures complied with the Guide for Care and Use of Agriculture Animals of Obihiro University.
The study used a multiple CL model to implant the MDS, as the CL formed after super-ovulation were shown to regress in response to a luteolytic injection of PGF 2a in a way that was very similar to that of intact CL (Miyamoto et al. 1998a) . This model enables us to examine in parallel several experimental infusions into the MDS implanted in the different CL (one MDS line/CL) within a ewe (Miyamoto et al. 1998a,b The experiments were conducted in October to December, during the breeding season. Mature Suffolk ewes were kept in a paddock under natural day length and temperature, and were fed a diet of concentrates and hay with water available ad libitum. All animals had at least two normal estrous cycles (16 or 17 days) before being used. The estrous cycles were based on progesterone concentrations in plasma taken every 3 days. In order to induce super-ovulation, ewes were pretreated according to the regimen of Miyamoto et al. (1998a,b) with an intra-vaginal sponge containing 60 mg medroxyprogesterone acetate (MPA, Repromap: The Upjohn Co. International Ltd, NSW, Australia) for 12 days. Pregnant mare's serum gonadotropin (200 IU) (Serotropin; Teikoku-zoki Co., Tokyo, Japan) was injected intramuscularly on the evening of the 9th day after the insertion of sponges, together with the first follicle-stimulating hormone (FSH) (6 mg Antorin 10; FSH of porcine origin, Denka Chemical Co., Kawasaki, Japan) injection. The FSH treatment comprised six intramuscular injections given at approximately 12-h intervals in a decreasing dose regimen (6, 6, 4, 4, 2, 2 mg) to give a total dose of 24 mg. The MPA sponges were withdrawn on the morning of the 12th day after the insertion. An injection of 100 mg synthetic gonadotropin releasing hormone (GnRH) (Conceral; Takeda Chemical Co., Osaka, Japan) was intramuscularly administered 24 h after the removal of the MPA sponges. The administration time of the GnRH injection was considered to be day 0. Daily blood samples (5 ml) for progesterone analysis in all experiments were collected through a jugular venous catheter over the whole period of the experiment, and the plasma samples were stored at 2 30 8C until assay.
Implantation of MDS into the CL
On day 7 after GnRH injection, several lines of MDS were surgically implanted into CL (one MDS line/CL) in both ovaries of animals as detailed earlier (Miyamoto et al. 1998a,b) . The CL formed after super-ovulation (5 -10 CL/ewe) were selected so as to have similar macroscopic characteristics (size, color and consistency). Each CL was penetrated with one capillary dialysis membrane (Fresenius SPS 900 Hollow Fibers, cut-off M r 1000 kDa, 0.2 mm diameter, 3 mm long; Fresenius AG, St Wendel, Germany). The capillary was affixed to the surface of the CL by Histoacryl Blue (B Braun-Dexon GmbH, Spangenberg, Germany). Both ends of the capillary were glued to 20-cm-long pieces of silastic tubing (i.d. 0.3 mm) that were connected to pieces of Teflon tubing leading to the outside of the abdomen. The exteriorized bundle of afferent and efferent Teflon tubes was taped to the body from the abdomen to the back with an adhesive bandage (Benefix; Japan Sigmax, Tokyo, Japan). The animals were brought to the pen where they were chained immediately after surgery. For perfusion, one end of the tube was connected to a peristaltic pump and the other was routed to a fraction collector. The CL were perfused with Ringer's solution at a flow rate of 1.5-ml/30 min/fraction throughout the experiments. The MDS lines of each animal were used for perfusion with substances on days 9 to 10. At least one line was used for Ringer's solution only (control) in each animal.
After 30-h perfusion, fractions of the perfusate were collected every 30 min for 32 to 48 h on days 9-11. After a period of 8 h for observing the spontaneous release of progesterone (baseline), further fractions were collected according to the experimental design. The transfer capacity of the microdialysis membrane was about 0.1% of the concentration infused as determined for OT, ET-1 and TNFa, and about 1% for progesterone and PGF 2a under the conditions used (Miyamoto et al. 1997 (Miyamoto et al. , 1998a . At the end of the experiments, the ewes were ovariectomized, and the CL were fixed in Bouin's solution, dehydrated in a graded series of ethanol, cleared in xylene and embedded in paraffin wax, and then processed for histology after hematoxylin -eosin staining. In most cases, little damage and no connective tissues such as fibroblasts were observed around the microdialysis capillary membrane.
Hormone determination
Progesterone, OT and ET-1 concentrations in the perfusate fractions from the MDS, and progesterone concentrations in plasma were determined with second-antibody enzyme immunoassays (EIAs) that were based on a competitive assay using a horseradish peroxidase-labeled progesterone (Miyamoto et al. 1992) or biotin-labeled peptides as tracers (Miyamoto et al. 1997) . Progesterone concentrations in plasma samples were assayed after extraction by diethyl ether, but those in the MDS fractions were assayed directly. The standard curve ranged from 0.05 to 50 ng ml 21 and the ED 50 of the assay was 1.8 ng ml
21
. The intra-and interassay coefficients of variation were on average 6.2% and 9.3% respectively.
For peptide extraction, 1-ml samples were taken from every fraction, and every 8 consecutive 1-ml samples (corresponding to a 4-h period) were pooled. BSA was added to each of the pooled samples to a final concentration of 1 mg ml
, and the solution was adjusted to pH 2.5 with 1 M acetic acid. The samples were then applied to a Sep-Pak C18 cartridge (Waters, Milford, MA, USA) according to the established method (Miyamoto et al. 1997) . The MDS fractions were concentrated 40-fold as a result of the process. The recoveries of synthetic OT and ET-1 added to Ringer's solution were 73% and 62% respectively (n ¼ 60). The EIAs for OT and ET-1 were conducted as described previously (Miyamoto et al. 1997) . The standard curve for OT ranged from 1.6 to 200 pg ml 21 and the ED 50 of the assay was 21 pg ml
. The intra-and interassay coefficients of variation of the OT assay were on average 6.2% and 8.6% respectively. The standard curve for ET-1 ranged from 9.7 to 5000 pg ml 21 and the ED 50 of the assay was 450 pg ml
. The intra-and interassay coefficients of variation of the ET-1 assay were on average 8.7% and 12.6% respectively.
Statistical analyses
The mean hormone concentrations in the first 8 h (progesterone was based on each 0.5-h fraction, and OT and ET-1 were based on each 4-h pooled fraction) were used to calculate the individual baseline, because of the large variation among individuals in the basal concentrations of each hormone released into the MDS. All hormone concentrations in the fractions were then expressed as a proportion of this individual baseline. This treatment enables an evaluation of the relative changes of hormonal values between the CL of different animals. The change in hormonal release after substance infusions was tested based on individual time points throughout the experiment as compared with the baseline. Means were analyzed by time-dependent repeated measures ANOVA followed by Student's t-test. Where a comparison among several treatment groups during the same time period was needed, means were analyzed by ANOVA followed by TukeyKramer test. For the figures showing MDS data, all hormonal concentrations were expressed as a percentage of the baseline with an 8 h basis. The absolute concentrations of the hormones in the MDS fractions (means^S.E.M.) are given in the figure legends.
Results
The super-ovulation treatment induced multiple CL (16.6^1.8; mean^S.E.M., n ¼ 12). There was no significant change in plasma progesterone levels during the MDS experiments, but the concentrations depended on the number of CL formed in each animal (8.2 -27.8 ng ml
21
).
Intra-luteal release of progesterone, OT and ET-1 in response to PGF 2a infusion
The release of hormones into the MDS from days 9 to 10 after GnRH was relatively constant over the experimental period. A 4-h perfusion with PGF 2a at 0.01 mmol l 21 , 0.1 mmol l
, or 1 mmol l 21 via the MDS induced no clear effect on progesterone release, but acutely stimulated OT release in a dose-dependent manner (P , 0.05; Fig. 1 ). The increase in OT was followed by a sustained drop after the stimulation. A 4-h perfusion with PGF 2a at 1 mmol l increased ET release over a period of 12 h (P , 0.05; Fig. 2 ), but the lower doses of PGF 2a at 0.01 mmol l 21 or 0.1 mmol l 21 did not affect ET-1 release.
Effect of pre-and simultaneous exposure with PGF 2a on the suppressing activity of ET-1 and TNFa
Two 4-h perfusions of ET-1 (0.1 mmol l
) between 12 and 16 h and 24 and 28 h decreased progesterone release between 24 and 48 h (78.2^2.8%; P , 0.05; Fig. 3  upper panel) . Likewise, a 4-h perfusion of ET-1 between 12 and 16 h and of TNFa (200 ng ml
) between 24 and 28 h decreased progesterone release between 24 and 48 h (76.2.^8.4%; P , 0.05; Fig. 3 upper panel) . A 4-h perfusion with PGF 2a (1 mmol l
) between 8 and 12 h slightly decreased progesterone release at 36 to 48 h (79.5^6.4%; P , 0.05; Fig. 3 lower panel) . When the CL were pre-perfused with PGF 2a for 4 h between 8 and 12 h, two consecutive perfusions of ET-1 between 12 and 16 h and 24 and 28 h rapidly decreased progesterone release between 16 and 48 h (74.6^5.9%; P , 0.05; Fig. 3 lower panel) ; this decrease occurred 8 h earlier than in the CL treated with ET-1 alone. Similarly, a pre-perfusion with PGF 2a for 4 h between 8 and 12 h, followed by consecutive perfusions of ET-1 between 12 and 16 h and of TNFa between 24 and 28 h, rapidly decreased progesterone release at 16 to 48 h (67.5^7.0%; P , 0.05; Fig. 3 lower panel) , but the inhibitory effect between 36 and 48 h was more pronounced than it was in the abovedescribed treatments (35.1^3.3%; P , 0.05; Fig. 3 lower  panel) . The simultaneous infusion of ET-1 and PGF 2a between 8 and 12 h induced a rapid and pronounced decrease in progesterone release (65.0^6.5%; P , 0.05; Fig. 3 lower panel) . ET-1 alone slightly stimulated OT release (403.7^72.6%; P , 0.05; Fig. 4 upper panel) . An infusion of PGF 2a between 8 and 12 h induced an acute release of OT (628.2^100.4%; P , 0.05; Fig. 4 lower  panel) . The simultaneous infusion of ET-1 and PGF 2a induced the highest stimulation in OT release (897.77 0.7%; P , 0.05; Fig. 4 lower panel) , followed by a drop for the next 12 h (52.9^16.0%; P , 0.05). ET-1 or TNFa after PGF 2a also stimulated OT release (666.9^123.4; P , 0.05; Fig. 4 lower panel) .
Comparison of the effects of PGF 2a , TPA and A23187
A 6-h perfusion with PGF 2a (10 mmol l
21
) between 8 and 14 h slightly increased progesterone release during infusion (P , 0.05), but did not affect it during the 16-h period after infusion (14 -30 h). A 6-h perfusion with TPA (10 mmol l 21 ), A23187 (10 mmol l 21 ), or PGF 2a together with A23187 between 8 and 14 h increased progesterone release during infusion more than with PGF 2a alone (P , 0.05), but induced a decrease in progesterone release after infusion, in the order A23187 (89%), TPA (67%), and PGF 2a þ A23187 (52%; Table 1 ). All three values were significantly different from each other (P , 0.05). All treatments induced a massive release of OT during infusion for OT. *P , 0.05, ***P , 0.001 compared with baseline.
(P , 0.05), whereas only A23187 and PGF 2a þ A23187 depressed OT release after infusion (P , 0.05). All treatments similarly increased ET-1 release after infusion (P , 0.05; Table 1 ).
Discussion
The results of the present study indicate that PGF 2a acts cooperatively with ET-1 and TNFa to suppress progesterone secretion in the ovine CL in vivo. Substances infused through the MDS act in the local microenvironment around the capillary membrane. Thus, the model used here does not have any major effect on the constriction of blood vessels in the whole CL, and hence excludes a direct effect on the vasoconstriction that was shown to be a crucial process for luteolysis (Niswender et al. 1976 , Azmi & O-Shea 1984 , Knickerbocker et al. 1988 , Acosta et al. 2002 . In this context, the present in vivo data may give basic and important information on the interaction of PGF 2a with ET-1 and TNFa in the cascade of functional luteolysis. It was observed in the present study that a single infusion of PGF 2a for 4 h did not change progesterone release in the CL up to 20 h after the infusion; notwithstanding the results of our similar in vivo investigation that a PGF 2a infusion to the bovine mid-cycle CL via MDS stimulated, but did not inhibit progesterone secretion (Ohtani et al. 1999) . These findings suggest that the countercurrent transfer of uterine or exogenous PGF 2a to the ovary plays a crucial role in inducing a rapid drop in progesterone release from the CL during luteolysis. On the other hand, ) could increase ET-1 release from the CL. This fact further supports the concept that a vasoconstriction of arterioles in the CL (Niswender et al. 1976 , Azmi & O-Shea 1984 , Knickerbocker et al. 1988 at the beginning of luteolysis may be attributed to the strong effect of ET-1 as well as of PGF 2a . It was observed in the present study that the simultaneous exposure of CL to PGF 2a and ET-1 was much more effective in reducing progesterone release than was the sequential exposure to these two compounds. Indeed, PGF 2a stimulates ET-1 release from ovine luteal cells (Hinckley & Milvae 2001) and it is this elevated local ET-1, stimulated by PGF 2a , together with the infused ET-1 which collectively act on the luteal cells, rather than a direct action of PGF 2a . This might result in a greater progesterone suppression when CL are exposured simultaneously to PGF 2a and ET-1. Our recent report revealed that PGF 2a and ET-1 cooperatively induce functional luteolysis of mid-cycle CL in the cow (Miyamoto et al. 2001) . We recently proposed that another vasoconstrictive peptide, angiotensin II (Ang II), might have a similar role. As in the case for ET-1, PGF 2a increases luteal Ang II release, and Ang II acts with PGF 2a as a suppressor of progesterone release in the bovine CL (Hayashi & Miyamoto 1999 , Hayashi et al. 2002 . In both vasoactive peptides, a concomitant perfusion of CL with PGF 2a had the greatest effect on progesterone suppression as observed in the present in vivo study, suggesting that these peptides are important luteal factors in inducing functional luteolysis.
Interestingly, PGF 2a did not suppress progesterone release in the present MDS model, but TPA, a stimulator of protein kinase C (PKC) clearly suppressed it. Moreover, TPA but not PGF 2a inhibited basal and low density lipoprotein-supported steroidogenesis in cultured regressing porcine luteal cells (Brannian et al. 1995) . Thus, TPA and PGF 2a have different effects on the CL. Stimulation of PKC in ovine large luteal cells was shown to be a dominant intracellular mechanism involved in progesterone suppression (Wiltbank et al. 1990 ). This was confirmed later using the in vivo model in which an infusion of TPA into the ovarian artery also decreased plasma progesterone concentrations (McGuire et al. 1994) . Our present in vivo data further support this concept. It appears that TPA infusion into the CL affects luteal progesterone release but differently in cows and ewes: TPA inhibited progesterone release in the ewe (the present result), while it did not affect progesterone release in the cow (Ohtani et al. 1999) . On the other hand, an infusion of A23187 slightly inhibited progesterone release in the ewe (the present result), but strongly inhibited it in the cow (Ohtani et al. 1999) . PGF 2a has been shown to increase the intracellular concentration of Ca 2þ in the luteal cells in both species (Davis et al. 1987 , Wiltbank et al. 1989 , Wegner et al. 1991 . Thus, there might be some difference between ewes and cows in cell sensitivity to PGF 2a at the second messenger level. This may be especially true in large luteal cells, in which a PKC pathway is dominant in the ewe, whereas an increase in Ca 2þ is a crucial function in the cow.
As a result of pharmacological stimulation of PKC and a calcium influx in the CL cells in vivo, a local release of OT was acutely stimulated during substance infusion while the ET-1 release was gradually stimulated after infusion. These data support the concept that Ca 2þ and PKC are responsible for the release of ET-1 and OT (CosolaSmith et al. 1990 , Masaki 1993 , Miyamoto et al. 1993 . These data also support the concept that OT is released from large luteal cells by granule exocytosis (Cosola-Smith et al. 1990 , Wathes & Denning-Kendall 1992 , while ET-1 secretion is a result of transcriptional activation of prepro-ET-1 followed by cleavage steps from big-ET-1 to ET-1 in endothelial cells (Masaki 1993) .
Our previous observation of a direct local effect of TNFa using the MDS implanted in the intact mid-cycle CL in the ewe showed that an infusion of TNFa alone induced a slight increase in the release of progesterone and PGF 2a , but it did not inhibit progesterone release (Miyamoto et al. 1995) . The effect of TNFa infusion was more or less similar when TNFa was perfused into the MDS implanted in the regressing CL in the same model (multiple CL) as the present study (Miyamoto et al. Table 1 Comparison of secretion rates of progesterone, OT, and ET-1 into the MDS implanted in the CL formed after super-ovulation among 5 treatment groups during (8-14 h) and after (14-30 h) stimulant infusion at 10 mmol l 21 in the ewe (n ¼ 4). Values are expressed as a percentage (means^S.E.M.) of the respective baseline (0-8 h). The baseline (100%) of progesterone release was 5.13^0.14 ng ml
21
, of OT release was 0.89^0.17 pg ml
, and of ET-1 release was 3.1^0.9 pg ml 1998a). However, the present results clearly indicated that TNFa is capable of decreasing progesterone release in the CL in vivo, if the CL is pre-treated by PGF 2a and ET-1. As an increase in local secretion of TNFa has been found in the regressing CL only after the completion of functional luteolysis in the ovine CL (Ji et al. 1991) and bovine CL (Shaw & Britt 1995) , the timing of the exposure of CL to TNFa may have a physiological meaning; TNFa may indeed be an effective suppressor of progesterone release when the luteal cells are stimulated by PGF 2a and ET-1 in vivo. In fact, a similar phenomenon was observed in an MDS study in pigs in which TNFa and PGF 2a synergistically inhibited steroidogenesis (Wuttke et al. 1997 (Wuttke et al. , 1998 . Therefore, a lack of up-regulation of TNFa mRNA in the regressing CL (Penny et al. 1999 , Petroff et al. 1999 may not exclude the possibility of such a synergism among PGF 2a , ET-1 and TNFa. Consequently, we speculate that during structural luteolysis, TNFa inhibits progesterone release, and at the same time it further stimulates a local release of ET-1, since endothelial cells are identified as target cells of cytokines and as cytokine-producing cells (Martin & Resch 1988) . ET-1, in turn, may stimulate TNFa secretion (Cunningham et al. 1997 , Ruetten & Thiemermann 1997 , thereby establishing a local positive feedback, which would accelerate the cascade of luteolysis. Indeed, the intra-luteal ET-1 concentration was shown to be maintained at a high level over the whole period of luteolysis in the cow (Ohtani et al. 1998) . In this regard, Meidan et al. (1999) proposed the same hypothesis on the basis of their results showing that ET-1 induces secretion of TNFa by bovine macrophages, and that luteal cells express the p55 type receptor for TNFa. Moreover, mRNA for TNFa was detected in luteal tissue around natural and induced luteolysis (Penny et al. 1999 ) and this increase was associated with an influx of macrophages into the CL around the time of the second half of luteolysis, possibly in response to monocyte chemoattractant protein (Webb et al. 2002) . Thus, the TNFa secreted by luteal cells and macrophages during structural luteolysis may interact with PGF 2a and ET-1, resulting in a rapid drop in progesterone release and accelerating the process of luteolysis. Collectively, the present results provide further evidence that ET-1 is capable of suppressing progesterone release in the PGF 2a -primed ovine CL in vivo. This observation supports the previous finding that the systemic administration of ET-1 potentiates the progesterone-suppressing activity of PGF 2a in the ewe (Hinckley & Milvae 2001) . The in vivo data obtained in the ewe (Hinckley & Milvae 2001, present study) , as well as the in vitro data obtained from the cow (Miyamoto et al. 1997) suggest that ET-1 alone cannot promote functional luteolysis. ET-1 works as a local luteolysin together with PGF 2a , and the CL needs to be triggered by PGF 2a to start the cascade of luteolysis in which ET-1 acts in response to the first stimuli of PGF 2a , causing a rapid drop in progesterone release. In conclusion, ET-1 and TNFa together with PGF 2a are capable of directly suppressing the local progesterone release in the ovine CL in vivo.
